Chopas James George 4

What Happened

• James G. Chopas, Vice President and Chief Accounting Officer of Apellis Pharmaceuticals (APLS), was granted 16,150 restricted stock units (RSUs) on January 28, 2026.
• The Form 4 reports an acquisition at $0.00 (transaction code A — Award). The filing shows no cash paid; the award is equity compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (filed within the typical two-business-day window).
• Reported security: 16,150 RSUs; price per share on Form 4: $0.00; total reported value on Form 4: $0.
• Vesting: These RSUs vest 25% annually over four years from the grant date, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing.
• Transaction code: A (Award/Grant). No tax-withholding sale, 10b5-1 plan, or late filing indicated in this filing.

Context

• RSUs are a form of compensation that convert to actual shares only as they vest; they do not represent immediately tradable shares until vesting and delivery.
• Grants like this are routine executive compensation and do not, by themselves, signal a buy or sell decision in the open market.